Prediction of Response to Neoadjuvant Chemotherapy: New Biomarker Approaches and Concepts

被引:11
作者
Denkert, Carsten [1 ]
Sinn, Bruno Valentin [1 ]
Issa, Yasmin [2 ]
Mueller, Berit Maria [1 ]
Maisch, Andrea [2 ]
Untch, Michael [3 ]
von Minckwitz, Gunter [2 ]
Loibl, Sibylle [2 ]
机构
[1] Charite Univ Med Berlin, Berlin, Germany
[2] German Breast Grp, Neu Isenburg, Germany
[3] Helios Klinikum Berlin Buch, Berlin, Germany
关键词
Neoadjuvant; Chemotherapy; Breast cancer; Lymphocytes; PARP; PARAFFIN-EMBEDDED TISSUE; OPERABLE BREAST-CANCER; DYING TUMOR-CELLS; ESTROGEN-RECEPTOR; IMMUNE-RESPONSE; POLY(ADP-RIBOSE) POLYMERASE-1; PREOPERATIVE CHEMOTHERAPY; ANTICANCER CHEMOTHERAPY; SYSTEMIC TREATMENT; MESSENGER-RNA;
D O I
10.1159/000331696
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
About 10-25% of breast cancer patients achieve a pathologically confirmed complete response after neoadjuvant chemotherapy. Tissue samples of pretreatment core biopsies are a valuable resource for translational research aiming towards predictive biomarkers for selecting patients who are likely to benefit from neoadjuvant therapy. The German Breast Group (GBG) and the AGO-B Group (AGO = Working Group Gynecological Oncology) have extensive experience in conducting neoadjuvant clinical trials. Technologies as immunohistochemistry on tissue microarrays and standardized reverse transcription-polymerase chain reaction (RT-PCR) approaches on formalin-fixed paraffin-embedded samples allow high-throughput investigation of protein and mRNA biomarkers. With these approaches, we could demonstrate that molecular tumor subtypes and immunological infiltrates are valuable and independent predictors of therapy response. New biomarkers such as poly(ADP-ribose) polymerase (PARP) might be useful for the prediction of response to conventional and new targeted therapies. This review summarizes current research projects focusing on biomarker discovery in the neoadjuvant setting.
引用
收藏
页码:265 / 272
页数:8
相关论文
共 62 条
[1]   LYMPHOCYTE INFILTRATES AS A PROGNOSTIC VARIABLE IN FEMALE BREAST-CANCER [J].
AALTOMAA, S ;
LIPPONEN, P ;
ESKELINEN, M ;
KOSMA, VM ;
MARIN, S ;
ALHAVA, E ;
SYRJANEN, K .
EUROPEAN JOURNAL OF CANCER, 1992, 28A (4-5) :859-864
[2]   Poly (ADP-Ribose) Polymerase as a Novel Therapeutic Target in Cancer [J].
Annunziata, Christina M. ;
O'Shaughnessy, Joyce .
CLINICAL CANCER RESEARCH, 2010, 16 (18) :4517-4526
[3]  
[Anonymous], SURV EP END RES 2008
[4]  
[Anonymous], CANC RES S2
[5]  
[Anonymous], ATL KREBS KREBSM 201
[6]  
[Anonymous], CANC RES S2
[7]  
[Anonymous], CANC RES S2
[8]  
[Anonymous], 2011, J CLIN ONCOL S
[9]  
[Anonymous], CANC RES S2
[10]   Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies [J].
Apetoh, Lionel ;
Tesniere, Antoine ;
Ghiringhelli, Francois ;
Kroemer, Guido ;
Zitvogel, Laurence .
CANCER RESEARCH, 2008, 68 (11) :4026-4030